Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus
host disease (GVHD) in patients following stem cell transplant from an unrelated donor. This
trial is designed to test the hypothesis that elimination of methotrexate in the unrelated
donor group would lead to less transplant-related toxicity while still preserving the
effective control of GVHD.